A multicentre, randomised, double-blind trial comparison in patients with moderate-to-severe essential hypertension showed that olmesartan medoxomil 20 mg/hydrochlorothiazide (HCTZ) 12.5 mg (n ¼ 308) produced greater blood pressure (BP) reductions than losartan 50 mg/HCTZ 12.5 mg (n ¼ 305). By week 12, mean sitting diastolic blood pressure (DBP) reductions (primary efficacy parameter) were 17.6 and 16.5 mmHg (intention-to-treat (ITT), P ¼ 0.0708), respectively and 18.2 and 16.7 mmHg; (per protocol (PP), P ¼ 0.0127). Moreover, by week 12 the proportion of controlled patients (BPo140/90 mmHg, 43.2% vs 32.1%, P ¼ 0.002), and the reduction in pulse pressure (11.679 .4 vs 8.479.4 mmHg, Po0.0001) was greater with olmesartan medoxomil/HCTZ than losartan/ HCTZ, indicating that olmesartan medoxomil 20 mg/HCTZ 12.5 mg offers better BP control in patients with moderate-to-severe hypertension.
Hypertension is a powerful risk factor for cardiovascular morbidity and mortality. Moderate-to-severe hypertension presents an increased risk for cardiovascular events 1 and is difficult to control. Indeed, the Hypertension Optimal Treatment (HOT) trial in grade 2 (moderate) and 3 (severe) hypertensive patients showed that only 25-40% of patients achieved target diastolic blood pressure (DBP) with monotherapy. 2 Recent US guidelines indicate treatment initiation with two agents, one of which is normally a thiazide diuretic, in patients whose blood pressure (BP) is 420 and 410 mmHg above systolic and diastolic goals, respectively. 3 Using two agents with different mechanisms of action is more likely to control hypertension, allows both agents to be given at lower dosages that are more likely to be better tolerated, and allows single-dosage administration, which optimises compliance. 4 ARBs are at least as effective as other antihypertensive drug classes in reducing BP, and have a tolerability profile comparable to placebo. 5 The current trial assessed the feasibility of a therapeutic approach to moderate-to-severe essential hypertension which involves initial combination therapy with two ARB/thiazide diuretic combination regimens: olmesartan medoxomil 20 mg/hydrochlorothiazide (HCTZ) 12.5 mg and losartan 50 mg/HCTZ 12.5 mg.
This randomised, double-blind trial was conducted in 9 European countries in accordance with ICH guidelines for GCP, the Declaration of Helsinki, and with local Independent Ethics Committees approval. All patients provided written informed consent prior to study entry.
A total of 766 male and female Caucasian outpatients aged X18 years with moderate-to-severe essential hypertension defined as either newly diagnosed without previous treatment (mean sitting DBP X100Àp120 mmHg and mean sitting systolic BP (SBP) X160 mmHg) or inadequately controlled (DBP 90À110 mmHg despite using X1 antihypertensive) were screened.
Exclusion criteria included secondary hypertension, very severe arterial hypertension (sitting DBP 4120 mmHg and/or SBP 4200 mmHg), significant liver, renal, cardiovascular or conduction diseases, dysarrhythmias and poorly controlled type 2 diabetes.
Patients on a-blockers, b-blockers or central sympatholytic drugs were tapered off for one week. After a 2-week placebo run-in, 629 patients were randomised to the fixed combination of olmesartan medoxomil 20 mg/HCTZ 12.5 mg (n ¼ 315) or losartan 50 mg/HCTZ 12.5 mg (n ¼ 314) once daily with breakfast for 12 weeks. 628 patients received X1 one dose of study medication (safety population) and of these, 613 (olmesartan/HCTZ n ¼ 308, losartan/ HCTZ n ¼ 305) had both a baseline plus X1 postbaseline sitting DBP value (intent-to-treat [ITT] population). No other antihypertensive drugs were permitted and patients with BP X160/100 mmHg were withdrawn after 8 weeks.
The olmesartan/HCTZ and losartan/HCTZ groups were comparable in demographic and baseline characteristics, including mean DBP (104.773.8 vs 104.473.4 mmHg, respectively) and SBP (169.77 8.7 vs 169.378.4 mmHg, respectively), mean duration of hypertension (6.476.3 vs 6.877.1 years, respectively). However, the proportion of severe hypertension patients was higher in the olmesartan/ HCTZ group (12.1 vs 5.4%).
Reductions in the primary efficacy variable (change from baseline at 12 weeks in mean trough sitting DBP assessed 2472 h after last dose by conventional sphygmomanometery) for olmesartan/ HCTZ and losartan/HCTZ were 17.6 and 16.5 mmHg (ITT analysis, difference 1.1 mmHg, P ¼ 0.0708; 95% CIs À0.09, 2.32) and 18.2 and 16.7 mmHg (PP analysis, difference 1.5 mmHg, P ¼ 0.0127; 95% CIs 0.33, 2.71).
Differences in BP-lowering efficacy between the two drugs were visible at week 1, and statistically significant at all timepoints for SBP (Pp0.0003) and at weeks 1, 4, and 8 for DBP (Pp0.0068, Figure 1) . By week 12, mean changes in DBP/SBP were À17.6/ À29.3 mmHg for olmesartan/HCTZ vs À16.5/ À24.9 mmHg for losartan/HCTZ.
Proportions of responders (DBP p90 mmHg and/ or decrease from baseline X10 mmHg) were higher for olmesartan/HCTZ than losartan/HCTZ at earlier timepoints, but similar for both groups by week 12 (81-86%). However, there was a greater proportion of controlled patients (SBP/DBP o140/90 mmHg) with olmesartan/HCTZ at all timepoints, and this was statistically significant at week 12 (43.2 vs 32.1%, P ¼ 0.002).
Reductions from baseline in pulse pressure were greater for olmesartan/HCTZ than losartan/ HCTZ at all timepoints, and were statistically significant at weeks 2, 4, 8, and 12 (Pp0.0017 for all, ITT population). By week 12, mean reductions in were 11.679.4 vs À8.479.4 mmHg, respectively (Po0.0001).
Both treatments were well tolerated with no remarkable differences between groups. There were no deaths, and five patients in each group had 15 treatment-emergent serious adverse events, all of which were classified as unrelated to treatment. The most frequently reported treatment-emergent adverse events (AEs) were dizziness (5.4 and 3.5% of olmesartan/HCTZ and losartan/HCTZ patients, respectively), headache (2.9 and 3.8%, respectively), back pain (1.6 and 3.2%, respectively), influenza (1.6 and 1.9%, respectively) and fatigue (1.3 and 1.9%, respectively). Reasons for patient withdrawal after randomisation for olmesartan/ HCTZ, losartan/HCTZ were: AEs (11,3), lack of efficacy (4,9), consent withdrawn (3,1), randomisation criteria not fulfilled (5, 5) , other reasons (10, 9) .
This study confirms the feasibility of an initial therapeutic strategy of combination antihypertensive therapy in patients with moderate-to-severe hypertension. In this difficult-to-treat population the combination of an ARB with a thiazide diuretic was associated with substantial reductions in both SBP and DBP, which must be interpreted in context of the absence of a placebo control. BP-lowering with olmesartan/HCTZ was numerically greater than with losartan /HCTZ. However, the difference in the primary endpoint was statistically significant only in the PP population, possibly due to greater variability from the inclusion of protocol violators in the ITT population. One issue is whether the observed difference (À1.1 mmHg for ITT and 1.5 mmHg for PP) is clinically relevant? Here, it should be noted that results of the CAPPP trial 6 and others, 7 indicate that a 2 mmHg difference in DBP could account for a 15% difference in risk of stroke and transient ischaemic attack.
In middle-aged and older patients, SBP is the main BP determinant of coronary heart disease risk. 8 Moreover, metaregression analysis of antihypertensive agents shows that odds ratios for cardiovascular outcomes could be explained by achieved differences in SBP. 9 Pulse pressure has also been shown to be a strong predictor of cardiovascular risk. 8 It has been suggested that antihypertensive treatment should reduce not only SBP and DBP, but also pulse pressure. 10 In our study, both SBP and pulse pressure reductions were significantly greater with olmesartan/HCTZ than with losartan/HCTZ. Time to onset of BP reduction is also clinically relevant. The early onset observed with olmesartan/ HCTZ, supports previous similar observations with olmesartan monotherapy. 11 The importance of early BP reduction was emphasised by the results of the VALUE trial. 12 The observed between-group difference in BP values in hypertensive patients with high cardiovascular risk was greatest during the first 6 months of treatment, and appeared to translate into an odds ratios difference in cardiovascular endpoints that favoured amlodipine. In our 3-month study, reductions in sitting DBP/SBP with olmesartan/HCTZ (12-18/21-30 mmHg, respectively) were greater than with losartan/HCTZ (11-17/17-25 mmHg, respectively). Since the VALUE findings suggest that recommended BP goals need to be achieved in weeks rather than months in high-risk patients, our data support the notion that initial combination treatment is a feasible approach. 
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